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Background: Tyrosine phosphorylation (pTyr) is an important cancer relevant posttranslational modification since it
regulates protein activity and cellular localization. By controlling cell growth and differentiation it plays an important
role in tumor development. This paper describes a novel approach for detection and visualization of a panel of pTyr
proteins in tumors using in situ proximity ligation assay.
Methods: K562 leukemia cells were treated with tyrosine kinase and/or phosphatase inhibitors to induce
differences in pTyr levels and mimic cells with different malignant properties. Cells were then probed with one
antibody against the pTyr modification and another probe against the detected protein, resulting in a detectable
fluorescent signal once the probes were in proximity.
Results: Total and protein specific pTyr levels on ABL, SHC, ERK2 and PI3K proteins were detected and samples of
control and treated cells were distinguished at the pTyr level using this novel approach. Promising results were also
detected for formalin fixed and paraffin embedded cells in the micro array format.
Conclusions: This application of in situ proximity ligation assay is valuable in order to study the pTyr modification
of a panel of proteins in large data sets to validate mass spectrometric data and to be combined with tissue
microarrays. The approach offers new opportunities to reveal the pTyr signatures in cells of different malignant
properties that can be used as biomarker of disease in the future.
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(in situ PLA)Background
Tyrosine phosphorylation (pTyr) of proteins is an import-
ant posttranslational modification (PTM) that regulates
many essential cellular functions [1]. The modification is
often involved in development and progression of cancer
[2,3]. The identification of this modification is therefore
important in order to understand systems biology. PTMs
such as phosphorylations of proteins are commonly iden-
tified by tandem mass spectrometric (MS) methods after
phosphopeptide enrichment via immunoaffinity or chem-
ical affinity methods [4-6]. The MS method is an excellent
approach to reveal the PTMs and to map specific amino
acids that carry the modifications on several different* Correspondence: sara.lind@kemi.uu.se
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unless otherwise stated.proteins. There is, however, a need for complementary
tools for i) confirming the findings, ii) for measuring the
abundance of a certain PTM in large collections of small
amounts of clinical tumor materials and iii) to reveal
PTMs on low-abundant proteins in complex matrices
where increased specificity is required. For this purpose, a
quantitative approach using MS detection is not the
method of choice. Instead a fast method that can handle
many samples at the same time e.g. using western blot-
ting, ELISAs or as presented in this study, proximity
ligation assays (PLA) with PTM specific antibodies is
advantageous.
The in situ PLA that was developed in 2006 is now an
established technique for detection of individual pro-
teins, protein-protein interactions [7] as well as PTMs in
cell lines and tissue sections [8-11]. Briefly, when DNA
oligonucleotides coupled to antibodies against differentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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to a couple of DNA oligonucleotides and template a
subsequent enzymatic ligation to form a circularized
DNA molecule. The newly formed circularized DNA
molecule will then be amplified using rolling circle ampli-
fication (RCA). The technology has unique specificity
due to the dual recognition and extreme sensitivity in the
pM-fM range in comparison to the sensitivity of shotgun
MS in the μM-nM range [12]. In addition, it provides
visualization of the cellular location of studied proteins.
In this study, we have applied the in situ PLA technol-
ogy for detection, visualization and quantification of the
abundance of pTyr using one phospho-tyrosine anti-
body and another antibody against the target protein.
The principle is described in Figure 1 and the assay was
developed for a panel of cancer-relevant proteins. The
combination of the antibodies allows specific detection
with an averaged pTyr signal for a selected protein,
which was then normalized to the number of cells to
get a quantitative value.
Methods
Chemicals
All chemicals were from Sigma Aldrich (St. Louis, MO,
USA) if not otherwise stated. The pTyr monoclonal anti-
body 4G10 was from Millipore (Billerica, MA, USA) and
the PYKD1 monoclonal antibody was purchased from
Sloan-Kettering Institute for Cancer Research (New York,
NY, USA). The protein specific primary polyclonal anti-
bodies used in this study were anti-c-ABL (sc-131) from
Santa Cruz Biotechnology (Santa Cruz, CA, USA),
anti-SHC (610082) from BD Transduction Laboratories
(Franklin Lakes, NJ, USA), anti-ERK2 (06–333) fromFigure 1 Schematic principle for the described in situ PLA for visualiz
against the detected protein was combined with an antibody against the p
nuclei are stained in blue.Millipore (Billerica, MA, USA), anti-PI3 kinase p110 β
(#3011) and anti-PI3 kinase p85 (#4292) from Cell
Signaling (Boston, MA, USA).
Cell culture
The leukemia K562 cells were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin (Gibco, Life Technologies,
Stockholm, Sweden). Before harvesting the cells, half
of the cell culture was treated with 50 μM Imatinib
(imatinib mesylate, Glivec or Gleevec, Novartis, Basel,
Switzerland) for 1 h or 100 μM pervanadate for 30 min.
Pervanadate was prepared from ortovanadate reacted with
0.05% hydrogen peroxide for 5 min. Excess of hydrogen
peroxide was removed by incubating the mixture at room
temperature (RT) with catalase to a final concentration of
200 μg/mL.
Cells were adjusted to a concentration of approxi-
mately 0.5×106 cells/mL by diluting with cell culture
medium. One mL cell cultures were then pelleted by
centrifugation, and washed once with PBS and twice
with Ca, Mg and NaHCO3 free PBS (Life Technologies,
Stockholm, Sweden). Both PBS solutions were supple-
mented with 1 mM Na3VO4. After the final wash, cells
were dissolved in 1 mL Ca, Mg and NaHCO3 free PBS
and kept at 4°C until use. Cells were spotted on glass slides
(Superfrost, Plus Gold, Thermo Scientific, Braunschweig,
Germany) with Shandon filter cards (Thermo Electron
Corporation, Runcorn Chesire, United Kindom) using
the cytospin technology (Cytospin 2, Shandon, Thermo
Fisher Scientific, Waltham, MA, USA). Briefly, 150 μL
of cell solution was added per glass holder (giving
approximately 75,000 cells per glass), and spun atation and detection of pTyr proteins in intact cells. An antibody
Tyr modification. Red dots represent detected pTyr proteins, while cell
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ice-cold ethanol for 30–60 minutes, thereafter the slides
were left to dry. Prepared slides were stored at −20°C until
used.In situ proximity ligation assay experiments
The in situ PLA experiments were performed using
reagents and instructions found in commercially avail-
able kits from Sigma-Aldrich; Duolink® In Situ PLA® Probe
Anti-Rabbit MINUS/PLUS (DUO92005/DUO92002),
Duolink® In Situ PLA® Probe Anti-Mouse MINUS/PLUS
(DUO92004/DUO92001) and Duolink® In Situ Detection
Reagents Orange (DUO92007). The fixed samples on the
slides were encircled with a hydrophobic pen (ImmEdge
Hydrophobic barrier pen, Vector Laboratories, art no.
H-4000) and rehydrated in 1 × TBS for 15 min. Forty
μL of blocking solution was added to each sample and
the slides were incubated in a humidity chamber for 1 h
at 37°C. Primary antibodies were diluted to final con-
centrations of 1 μg/mL, except for anti-SHC antibody
that was used at 0.1 μg/mL concentration. When using
only the 4G10 antibody in in situ PLA, the range of
0.1-1 μg/mL was used. Blocking solution was removed
and 40 μL of primary antibody mix was added to cor-
responding sample, and slides were incubated in a
humidity chamber overnight (approximately 22 h) at
4°C. Secondary probes were diluted to final concentra-
tions of 1:5 in antibody diluent (supplied in the kit).
Primary antibody solution was removed and the slides
were washed in 1 × TBS 0.05% Tween 20 (TBS-T) for
2 × 5 min with gentle agitation (shaker set at ~60 rpm)
(hereby referred to as the washing procedure) before
40 μL of the secondary probes mix was added to each
sample. The slides were incubated in a humidity chamber
for 1 h at 37°C, washed (see washing procedure), and
thereafter 40 μL ligation solution was added to each
sample. The slides were then incubated in a humidity
chamber for 30 min at 37°C, ligation solution was
removed, slides were washed (see washing procedure),
and 40 μL amplification solution (MilliQ H2O, Amplifi-
cation/detection mix, polymerase) was added to each
sample. The slides were incubated in a humidity cham-
ber for 100 min at 37°C. Slides were then washed briefly
in 1× TBS before 40 μL of 100 µg/mL (in 1 × TBS) of
Hoechst dye (Life Technologies, art. No. H1399) was
added to each sample to stain cell nuclei for fluores-
cence microscopy. Samples were incubated in dark for
1 h at RT and then washed in dark in MQ water over
night. Before detection, 10 μL of mounting media (Slow
Fade Gold Antifade Reagent, Life Technologies, art.
No. S36936) was added to each sample and covered
with a cover slip. Edges of the cover slip were sealed
with nail polish. Slides were stored at 4°C.Microscopy and data handling
The results were viewed with an epifluorescence micro-
scope (Axioplan II, Zeiss, Germany) and stacked TIFF files
were obtained using Axiovision 4.8 (Zeiss, Germany), with
a maximum slice distance of 0.5 μm in order to image
every PLA signal. Since the number of signals per cell
can vary within a sample mainly due to that cells are
in different stages of cell cycle, but also because of
local differences in reagent concentration, cell conflu-
ences and drying, a minimum of at least five images
were taken for each sample at various sites on the
slide. Also, in order to account for the cell-to-cell
variation in the number of signals per cell, and to ob-
tain significant quantifications, a total numbers of
100–200 cells were imaged from each sample. The
images were analyzed in Duolink image tool (Sigma-
Aldrich, Germany), the drawing tool was used to ex-
clude background signals on the slide and partial cells.
The quantifications were exported to Excel and the
numbers of nuclei were controlled manually for each
image within the drawn area. Data were compiled
along with standard deviations. Statistical analyses were
performed in GraphPad Prism (GraphPad software Inc.,
La Jolla, CA, USA). Signals for each experiment were
plotted in a diagram with marked average and bars
corresponding to 95% confidence intervals to visualize the
significance level of experiments. Two outliers were
removed (in two different experiments) after statistic
outlier test.
Formalin fixed paraffin embedded samples
Forty-six in vitro cultured cell lines (among others the
K562 and U937 cell lines) representing different cell
types were fixed in formalin after harvest. The fixed cells
were then mixed with melted agarose, in order to create
a block of dispersed single cells in a 3D matrix. The
resulting cell gels were subjected to standard histopro-
cessing, paraffin embedding, and finally assembled in a
cell microarray format [13].
Western blot
Western blot were used to evaluate the performance of
primary antibodies used, and is further described in
Additional file 1.
Results and discussion
The pTyr modification is a disease relevant PTM since
its dysregulation can lead to uncontrolled growth, which is
a hallmark of cancer. It is therefore of importance to
evaluate novel approaches that can be used for its detec-
tion. Compared with MS detection, in situ PLA-based
detection of pTyr proteins can be performed using much
less material, and there is no need for extensive sample
preparation before measurement. Therefore, larger sample
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cation and pTyr sites discovered by MS detection can also
be verified since the two methods have different selectivity
mechanisms and should be considered complementary.
Furthermore, the in situ PLA can be applied on intact
cells and tissue sections, also enabling determination of
localization and a tool to follow the dynamics in the
localization of the pTyr proteins in the cells. In this study
we present a general approach for analysis of the overall
pTyr pattern form all pTyr proteins as well as an estab-
lished protocol to detect the pTyr levels for a panel of
specific cancer relevant proteins. In the in situ PLA used
in this study one antibody against the target protein was
combined with an anti-pTyr antibody (Figure 1). An aver-
age value of the pTyr level of the protein was then
detected, but site specific information was not available.
The usage of a general pTyr antibody instead of expensive
site-and-protein-specific pTyr antibodies, leads to a
reduced cost and therefore wider applicability of this
method. The model system for testing the PLA ap-
proach for pTyr proteins was the K562 leukemia cell
line. This cell line expresses the BCR-ABL fusion pro-
tein, and the ABL kinase is constitutively active and
produces an overall relatively high pTyr level. Since the
ABL kinase can be controlled via imatinib treatment – a
tyrosine kinase inhibitor (TKI) that decreases the pTyr
levels – a measurable difference is introduced. Further,
since the K562 cell line responds to pervanadate treat-
ment – a general tyrosine phosphatase inhibitor (TPI) –
an induced increase in pTyr levels can be established.
Previously, we described characterization of more than
200 pTyr proteins in the K562 cell line using MS detec-
tion [14] from which a subset was selected for this study
to be tested by in situ PLA.
Reagents for PLA are commercially available, but upon
use for studying biological events, evaluation of antibody
performance is highly necessary. In the presented study,
antibody specificity and ability to quantify induced dif-
ferences in cellular systems with respect to pTyr levels
were evaluated. Initial experiments demonstrated the
compatibility of the in situ PLA reagents and the twoFigure 2 In situ PLA for visualization of total pTyr levels. K562 cells pro
(panel B) compared to negative control (panel C) where the primary antib
nuclei are stained in blue. Scale bars 10 μm.anti-pTyr antibodies, 4G10 and PYKD1. In each experi-
ment either the 4G10 or the PYKD1 antibody was com-
bined with secondary anti-mouse antibodies carrying
both plus and minus oligonucleotides to enable ligation
and signal detection. In this way the overall pTyr profile
from all pTyr proteins in a cell was visualized (Figure 2).
As can be seen in Figure 2A and B, the 4G10 antibody
recognized more pTyr sites than the PYKD1 antibody.
This is in agreement with results obtained with western
blotting and MS [15]. Therefore the 4G10 antibody was
the first choice when later on detecting pTyr signals on
specific proteins. In a negative control experiment where
the primary pTyr antibodies were omitted, no signals
were observed, demonstrating the requirement of the
anti-pTyr antibodies for signal detection (Figure 2C). In
the next step, perturbations were introduced by treating
cells with either the TKI imatinib to decrease the pTyr
levels, or with the TPI pervanadate to increase the pTyr
levels. The PLA results are visualized in Figure 3A and
the corresponding quantitations of pTyr signals are pre-
sented in Figure 3B. The results confirmed that expected
differences in pTyr levels can be detected with this pTyr
assay. A control experiment, using only protein specific
antibody together with anti-rabbit secondary antibodies
with both plus and minus oligonucleotides attached in
the in situ PLA reaction showed similar signals before
and after stimulation. This verified that the protein levels
were not significantly altered by the treatments. The
treatment was therefore concluded to only have an effect
on the pTyr levels of the proteins, which certifies the
model system.
To further study the pTyr signals on specific proteins
the ABL, ERK2/MAPK1, SHC and PI3K (p110β and
p85β units) proteins were selected. The protein specific
antibodies were first tested for their selectivity to their
cognate proteins in a cell lysate of K562 cells in western
blot experiments (see Additional file 1). Antibodies that
produced a single or a dominating protein band at
expected molecular weight in this analysis were selected
for in situ PLA analysis to assure specificity of anti-
bodies. Not all evaluated antibodies passed this test.bed in in situ PLA with anti-pTyr antibodies 4G10 (panel A) and PYKD1
ody omitted. Red dots represent detected pTyr proteins, while cell
Figure 3 In situ PLA for visualization and quantification of total pTyr levels. K562 cells probed in in situ PLA with anti-pTyr antibodies PYKD1
and 4G10. Untreated control cells, C-PYKD1 and C-4G10, are compared to cells treated with tyrosine kinase inhibitor (TKI) and tyrosine phosphatase
inhibitors (TPI), respectively, to investigate whether the assay is able to measure introduced perturbations. A) Visualization by fluorescent images: Red
dots represent detected pTyr signals, cell nuclei are stained in blue and cytoplasms in green. Scale bars 10 μm. B) Quantification: The number of total
pTyr signals per cell in a diagram. Bars represent average with 95% confidence interval.
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PLA experiments are presented in Additional file 1. For
proteins regulated by the BCR-ABL tyrosine kinase
(ABL, ERK2 and SHC) in K562 cells, expected and
significant changes in pTyr levels were observed upontreatment with imatinib while PI3K was only found to
be sensitive to TPI treatment. The results are visualized in
Figure 4A and quantified in Figure 4B. Compared to
Figure 2A when only the 4G10 antibody was used to
visualize all pTyr proteins, fewer signals were observed
Figure 4 (See legend on next page.)
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Figure 4 In situ PLA for visualization and quantification of protein specific pTyr levels. K562 cells probed in in situ PLA with anti-pTyr
antibody, 4G10, combined with protein specific antibodies (specified in figure) for control cells (C), cells treated with tyrosine kinase inhibitor
(TKI, imatinib) (ABL, SCH, ERK2) and cells treated with tyrosine phosphatase inhibitor (TPI, pervanadate) (PI3K p110β and p85β). A) Visualization by
fluorescent pictures: Red dots represent detected pTyr signals, cell nuclei are stained in blue and cytoplasms stained in green. Scale bars 10 μm.
B) Quantification: The number of pTyr signals per cell for different proteins are presented in a diagram. Bars represent mean with 95% confidence
interval. The PI3K protein (p110β unit) was found sensitive to TPI but not to TKI treatment. The results for the ERK2 protein are enlarged to
visualize that there was a significant difference between control and treated cells.
Elfineh et al. BMC Cancer 2014, 14:435 Page 7 of 8
http://www.biomedcentral.com/1471-2407/14/435when the 4G10 was combined with another antibody
for detection of a specific phosphorylated protein. Ima-
tinib treatment of K562 cells is a well characterized
model system [16,17] and it was chosen since reference
data was available. Data from a complementary tech-
nique is very valuable when implementing novel ap-
proaches as this paper describes. Therefore, the results
for the ABL, SHC and ERK2 proteins were compared
with data from a MS-based measurement. For the pTyr
sites Y115 and Y393 on ABL, and the pTyr site Y427 on
SHC the ratio between control and treated has previ-
ously been reported to be >10, while the ratio for the
Y187 site on ERK2 only was >2 in the K562 cell line
using an MS based approach [17]. This is in agreement
with our results where a ratio of two was observed for
ERK2 and a ratio of six was observed for ABL and SHC.
Since these proteins showed a measurable signal differ-
ence in the PLA upon imatinib treatment, a validated
drug for treatment of chronic myeloid leukemia, they
were therefore not further evaluated with pervanadate.
The fact that the PI3K protein was non-sensitive to the
TKI treatment agreed with previous reports that PI3K is
not part of the BCR-ABL signature [17]. Pervanadate
was used to verify the ability of the PLA set-up ability to
measure pTyr differences for that protein. This proves
that the described assay can detect changes in pTyr
levels for PI3K even though the protein is insensitive
to imatinib treatment. The same trend for increasedFigure 5 In situ PLA for pTyr proteins applied to the micro array form
(Panel B) cells assembled in a micro array format reacted with 4G10 antibo
pTyr signals while nuclei and cytoplasms are stained in blue and green, ressignals upon TPI treatment were observed for both
PI3K antibodies tested, but the difference in signal
intensities observed shows that antibody selection is an
important step in assay development Compared to an
MS based approach [15,17], with requirement of 2×108
cells per reaction and several days extensive sample
preparation – such as immunoaffinity enrichment of
pTyr peptides – the presented PLA approach requires
only 7.5×104 cells and negligible sample preparation.
Thus, the PLA approach should be considered a highly
valuable alternative for pTyr profiling for targeted
analysis of selected proteins. Furthermore, the PLA
approach reveals information on the cellular localization
of pTyr proteins.
In the future, it would be highly valuable if the pTyr
modification could be detected in large sample sets,
e.g. in formalin fixed samples on tissue micro arrays
(TMAs). The compatibility of the pTyr PLA to forma-
lin fixed and paraffin embedded samples was evaluated
for the two formalin fixed leukemia cell lines K562 and
U937 by using the 4G10 antibody in an overall pTyr
assay (Figure 5). Our limited experiments demonstrate
that the tested pTyr antibodies work in this format.
However, the signals observed were fewer compared to
the signals observed in cells fixed with ethanol directly
on the glass slide and the background in the TMA for-
mat was considerably higher, which can be due to that
the cells are broken upon slicing the artificial tissueat. Formalin fixed and paraffin embedded K562 (Panel A) and U937
dy in in situ PLA to visualize the pTyr modification. Red dots represent
pectively. Scale bars 10 μm.
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compartments. Further, the protocol applied for the
assay was the same as for using the in situ PLA on
ethanol fixed cells, i.e. not optimized, but the observa-
tion of signals is an important step in the development
since it opens up for fast investigation of many clinical
tumor samples available on TMAs in the future.
Conclusions
Development of new approaches to study the pTyr mod-
ifications is of great importance and is likely to improve
the understanding of cellular signaling and thereby dis-
ease related events. In the future, pTyr signature pat-
terns are likely to enable classification of tumors and to
reveal perturbed pathways. As described in this paper,
the in situ PLA method using one antibody against the
phosphorylation and another against the specific protein
is a successful approach. In this way perturbations in
pTyr levels can be detected with cellular resolution in
small sample amounts.
Additional file
Additional file 1: Antibody evaluation with western blotting.
Description on how evaluation of antibodies was performed with
western blotting before they were used in proximity ligation assay.
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